826 related articles for article (PubMed ID: 29109393)
1. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.
Adalsteinsson VA; Ha G; Freeman SS; Choudhury AD; Stover DG; Parsons HA; Gydush G; Reed SC; Rotem D; Rhoades J; Loginov D; Livitz D; Rosebrock D; Leshchiner I; Kim J; Stewart C; Rosenberg M; Francis JM; Zhang CZ; Cohen O; Oh C; Ding H; Polak P; Lloyd M; Mahmud S; Helvie K; Merrill MS; Santiago RA; O'Connor EP; Jeong SH; Leeson R; Barry RM; Kramkowski JF; Zhang Z; Polacek L; Lohr JG; Schleicher M; Lipscomb E; Saltzman A; Oliver NM; Marini L; Waks AG; Harshman LC; Tolaney SM; Van Allen EM; Winer EP; Lin NU; Nakabayashi M; Taplin ME; Johannessen CM; Garraway LA; Golub TR; Boehm JS; Wagle N; Getz G; Love JC; Meyerson M
Nat Commun; 2017 Nov; 8(1):1324. PubMed ID: 29109393
[TBL] [Abstract][Full Text] [Related]
2. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
3. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
[TBL] [Abstract][Full Text] [Related]
4. Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Butler TM; Johnson-Camacho K; Peto M; Wang NJ; Macey TA; Korkola JE; Koppie TM; Corless CL; Gray JW; Spellman PT
PLoS One; 2015; 10(8):e0136407. PubMed ID: 26317216
[TBL] [Abstract][Full Text] [Related]
5. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
[TBL] [Abstract][Full Text] [Related]
6. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy by NGS: differential presence of exons (DPE) in cell-free DNA reveals different patterns in metastatic and nonmetastatic colorectal cancer.
Olmedillas-López S; García-Olmo DC; García-Arranz M; Peiró-Pastor R; Aguado B; García-Olmo D
Cancer Med; 2018 May; 7(5):1706-1716. PubMed ID: 29573240
[TBL] [Abstract][Full Text] [Related]
8. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
9. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
10. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
11. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
[TBL] [Abstract][Full Text] [Related]
12. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
13. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
[TBL] [Abstract][Full Text] [Related]
14. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.
Manier S; Park J; Capelletti M; Bustoros M; Freeman SS; Ha G; Rhoades J; Liu CJ; Huynh D; Reed SC; Gydush G; Salem KZ; Rotem D; Freymond C; Yosef A; Perilla-Glen A; Garderet L; Van Allen EM; Kumar S; Love JC; Getz G; Adalsteinsson VA; Ghobrial IM
Nat Commun; 2018 Apr; 9(1):1691. PubMed ID: 29703982
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy in Gastric Cancer: Analysis of Somatic Cancer Tissue Mutations in Plasma Cell-Free DNA for Predicting Disease State and Patient Survival.
Varkalaite G; Forster M; Franke A; Kupcinskas J; Skieceviciene J
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00403. PubMed ID: 34644276
[TBL] [Abstract][Full Text] [Related]
16. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Parikh AR; Leshchiner I; Elagina L; Goyal L; Levovitz C; Siravegna G; Livitz D; Rhrissorrakrai K; Martin EE; Van Seventer EE; Hanna M; Slowik K; Utro F; Pinto CJ; Wong A; Danysh BP; de la Cruz FF; Fetter IJ; Nadres B; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Giantonio B; Murphy JE; Nipp RD; Roeland E; Ryan DP; Weekes CD; Kwak EL; Faris JE; Wo JY; Aguet F; Dey-Guha I; Hazar-Rethinam M; Dias-Santagata D; Ting DT; Zhu AX; Hong TS; Golub TR; Iafrate AJ; Adalsteinsson VA; Bardelli A; Parida L; Juric D; Getz G; Corcoran RB
Nat Med; 2019 Sep; 25(9):1415-1421. PubMed ID: 31501609
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer.
Mo H; Wang X; Ma F; Qian Z; Sun X; Yi Z; Guan X; Li L; Liu B; Xu B
Breast; 2020 Oct; 53():111-118. PubMed ID: 32738630
[TBL] [Abstract][Full Text] [Related]
18. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
[TBL] [Abstract][Full Text] [Related]
19. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
[TBL] [Abstract][Full Text] [Related]
20. Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study.
Ritter M; Paradiso V; Widmer P; Garofoli A; Quagliata L; Eppenberger-Castori S; Soysal SD; Muenst S; Ng CKY; Piscuoglio S; Weber W; Weber WP
Clin Breast Cancer; 2020 Oct; 20(5):413-421.e1. PubMed ID: 32650988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
